- Home
- USNA vs AUTL Comparison
USNA vs AUTL Comparison
Compare USNA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USNA
- AUTL
- Stock Information
- Founded
- USNA 1992
- AUTL 2014
- Country
- USNA United States
- AUTL United Kingdom
- Employees
- USNA N/A
- AUTL N/A
- Industry
- USNA Medicinal Chemicals and Botanical Products
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USNA Health Care
- AUTL Health Care
- Exchange
- USNA Nasdaq
- AUTL Nasdaq
- Market Cap
- USNA 565.5M
- AUTL 433.8M
- IPO Year
- USNA 1996
- AUTL 2018
- Fundamental
- Price
- USNA $20.53
- AUTL $1.41
- Analyst Decision
- USNA Hold
- AUTL Strong Buy
- Analyst Count
- USNA 1
- AUTL 5
- Target Price
- USNA $36.00
- AUTL $9.12
- AVG Volume (30 Days)
- USNA 415.8K
- AUTL 2.6M
- Earning Date
- USNA 10-22-2025
- AUTL 11-12-2025
- Dividend Yield
- USNA N/A
- AUTL N/A
- EPS Growth
- USNA N/A
- AUTL N/A
- EPS
- USNA 0.89
- AUTL N/A
- Revenue
- USNA $912,670,000.00
- AUTL $29,934,000.00
- Revenue This Year
- USNA $9.77
- AUTL $643.50
- Revenue Next Year
- USNA $2.69
- AUTL $108.69
- P/E Ratio
- USNA $22.92
- AUTL N/A
- Revenue Growth
- USNA 5.88
- AUTL 185.17
- 52 Week Low
- USNA $18.70
- AUTL $1.11
- 52 Week High
- USNA $41.84
- AUTL $4.12
- Technical
- Relative Strength Index (RSI)
- USNA 35.40
- AUTL 40.92
- Support Level
- USNA $19.45
- AUTL $1.46
- Resistance Level
- USNA $21.60
- AUTL $1.63
- Average True Range (ATR)
- USNA 0.88
- AUTL 0.10
- MACD
- USNA 0.31
- AUTL -0.02
- Stochastic Oscillator
- USNA 63.86
- AUTL 2.56
About USNA USANA Health Sciences Inc.
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.